These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

484 related articles for article (PubMed ID: 30506283)

  • 21. Peptide receptor radionuclide therapy with ¹⁷⁷Lu-DOTATATE: the IEO phase I-II study.
    Bodei L; Cremonesi M; Grana CM; Fazio N; Iodice S; Baio SM; Bartolomei M; Lombardo D; Ferrari ME; Sansovini M; Chinol M; Paganelli G
    Eur J Nucl Med Mol Imaging; 2011 Dec; 38(12):2125-35. PubMed ID: 21892623
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Peptide receptor radionuclide therapy (PRRT) in European Neuroendocrine Tumour Society (ENETS) grade 3 (G3) neuroendocrine neoplasia (NEN) - a single-institution retrospective analysis.
    Thang SP; Lung MS; Kong G; Hofman MS; Callahan J; Michael M; Hicks RJ
    Eur J Nucl Med Mol Imaging; 2018 Feb; 45(2):262-277. PubMed ID: 28894897
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety of multiple repeated cycles of
    Yordanova A; Mayer K; Brossart P; Gonzalez-Carmona MA; Strassburg CP; Essler M; Ahmadzadehfar H
    Eur J Nucl Med Mol Imaging; 2017 Jul; 44(7):1207-1214. PubMed ID: 28246882
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-Term Efficacy, Survival, and Safety of [
    Brabander T; van der Zwan WA; Teunissen JJM; Kam BLR; Feelders RA; de Herder WW; van Eijck CHJ; Franssen GJH; Krenning EP; Kwekkeboom DJ
    Clin Cancer Res; 2017 Aug; 23(16):4617-4624. PubMed ID: 28428192
    [No Abstract]   [Full Text] [Related]  

  • 25. Early prediction of tumour response to PRRT. The sequential change of tumour-absorbed doses during treatment with 177Lu-octreotate.
    Ezziddin S; Reichmann K; Yong-Hing C; Damm M; Risse J; Ahmadzadehfar H; Logvinski T; Guhlke S; Biersack HJ; Sabet A
    Nuklearmedizin; 2013; 52(5):170-7. PubMed ID: 23963021
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Peptide Receptor Radionuclide Therapy in the Treatment of Neuroendocrine Tumors.
    Kwekkeboom DJ; Krenning EP
    Hematol Oncol Clin North Am; 2016 Feb; 30(1):179-91. PubMed ID: 26614376
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical Assessment of 177Lu-DOTATATE Quantification by Comparison of SUV-Based Parameters Measured on Both Post-PRRT SPECT/CT and 68Ga-DOTATOC PET/CT in Patients With Neuroendocrine Tumors: A Feasibility Study.
    Thuillier P; Maajem M; Schick U; Blanc-Beguin F; Hennebicq S; Metges JP; Salaun PY; Kerlan V; Bourhis D; Abgral R
    Clin Nucl Med; 2021 Feb; 46(2):111-118. PubMed ID: 33234927
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Outcome of peptide receptor radionuclide therapy with 177Lu-octreotate in advanced grade 1/2 pancreatic neuroendocrine tumours.
    Ezziddin S; Khalaf F; Vanezi M; Haslerud T; Mayer K; Al Zreiqat A; Willinek W; Biersack HJ; Sabet A
    Eur J Nucl Med Mol Imaging; 2014 May; 41(5):925-33. PubMed ID: 24504504
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Specific efficacy of peptide receptor radionuclide therapy with (177)Lu-octreotate in advanced neuroendocrine tumours of the small intestine.
    Sabet A; Dautzenberg K; Haslerud T; Aouf A; Sabet A; Simon B; Mayer K; Biersack HJ; Ezziddin S
    Eur J Nucl Med Mol Imaging; 2015 Jul; 42(8):1238-46. PubMed ID: 25808630
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [(111)In-DTPA]octreotide tumor uptake in GEPNET liver metastases after intra-arterial administration: an overview of preclinical and clinical observations and implications for tumor radiation dose after peptide radionuclide therapy.
    Pool SE; Kam BL; Koning GA; Konijnenberg M; Ten Hagen TL; Breeman WA; Krenning EP; de Jong M; van Eijck CH
    Cancer Biother Radiopharm; 2014 May; 29(4):179-87. PubMed ID: 24820805
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy: Dose Response in Small Intestinal Neuroendocrine Tumors.
    Jahn U; Ilan E; Sandström M; Garske-Román U; Lubberink M; Sundin A
    Neuroendocrinology; 2020; 110(7-8):662-670. PubMed ID: 31597134
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Three-dimensional radiobiological dosimetry of kidneys for treatment planning in peptide receptor radionuclide therapy.
    Baechler S; Hobbs RF; Boubaker A; Buchegger F; He B; Frey EC; Sgouros G
    Med Phys; 2012 Oct; 39(10):6118-28. PubMed ID: 23039651
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0),Tyr(3)-octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate.
    Valkema R; Pauwels SA; Kvols LK; Kwekkeboom DJ; Jamar F; de Jong M; Barone R; Walrand S; Kooij PP; Bakker WH; Lasher J; Krenning EP
    J Nucl Med; 2005 Jan; 46 Suppl 1():83S-91S. PubMed ID: 15653656
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Peptide Receptor Radionuclide Therapy of Late-Stage Neuroendocrine Tumor Patients with Multiple Cycles of
    Liu Q; Zang J; Sui H; Ren J; Guo H; Wang H; Wang R; Jacobson O; Zhang J; Cheng Y; Zhu Z; Chen X
    J Nucl Med; 2021 Mar; 62(3):386-392. PubMed ID: 32826319
    [TBL] [Abstract][Full Text] [Related]  

  • 35. First-in-Humans Study of the SSTR Antagonist
    Baum RP; Zhang J; Schuchardt C; Müller D; Mäcke H
    J Nucl Med; 2021 Nov; 62(11):1571-1581. PubMed ID: 33674401
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of dead time on quantitative
    Desy A; Bouvet GF; Frezza A; Després P; Beauregard JM
    EJNMMI Phys; 2020 May; 7(1):32. PubMed ID: 32415492
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Peptide Receptor Radionuclide Therapy With 177Lu-Octreotate in Patients With Somatostatin Receptor Expressing Neuroendocrine Tumors: Six Years' Assessment.
    Hamiditabar M; Ali M; Roys J; Wolin EM; OʼDorisio TM; Ranganathan D; Tworowska I; Strosberg JR; Delpassand ES
    Clin Nucl Med; 2017 Jun; 42(6):436-443. PubMed ID: 28263217
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety and Effectiveness of 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy After Regional Hepatic Embolization in Patients With Somatostatin-Expressing Neuroendocrine Tumors.
    Hamiditabar M; Ali M; Bolek L; Vahdati G; Tworowska I; Delpassand ES
    Clin Nucl Med; 2017 Nov; 42(11):822-828. PubMed ID: 28832377
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Could the skewness and kurtosis texture parameters of lesions obtained from pretreatment Ga-68 DOTA-TATE PET/CT images predict receptor radionuclide therapy response in patients with gastroenteropancreatic neuroendocrine tumors?
    Önner H; Abdülrezzak Ü; Tutuş A
    Nucl Med Commun; 2020 Oct; 41(10):1034-1039. PubMed ID: 32516240
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Improving quality of life in patients with pancreatic neuroendocrine tumor following peptide receptor radionuclide therapy assessed by EORTC QLQ-C30.
    Marinova M; Mücke M; Mahlberg L; Essler M; Cuhls H; Radbruch L; Conrad R; Ahmadzadehfar H
    Eur J Nucl Med Mol Imaging; 2018 Jan; 45(1):38-46. PubMed ID: 28864881
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.